Epigenomics AG / Key word(s): Corporate Action 19.12.2013 09:40 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin, Germany, December 19, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces the successful […]
Year: 2013
19. December 2013
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG announces placement of maximal amount of convertible bonds
Read more
13. December 2013
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG sets conversion price
Epigenomics AG / Key word(s): Corporate Action 13.12.2013 19:49 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics […]
12. December 2013
Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
Epigenomics AG / Key word(s): Miscellaneous 12.12.2013 / 08:45 Berlin, Germany, and U.S.A., December 12, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the […]
04. December 2013
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG issues convertible bonds of up to EUR 2.68m
Epigenomics AG / Key word(s): Corporate Action 04.12.2013 01:09 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin, Germany, December 3, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces that its […]
04. December 2013
Epigenomics AG: Epigenomics AG Secures Additional Financing
Epigenomics AG / Key word(s): Corporate Action 04.12.2013 / 09:20 Berlin, Germany, and U.S.A., December 4, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that it has obtained a commitment for an additional financing. Through the issuance of convertible bonds, the Company will immediately receive […]
29. November 2013
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG / Veröffentlichung der Gesamtzahl der Stimmrechte 29.11.2013 10:45 Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG, übermittelt durch die DGAP – ein Unternehmen der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ————————————————————————— Hiermit teilt die Epigenomics AG mit, dass die Gesamtzahl der Stimmrechte am Ende des Monats […]